Literature DB >> 25960303

Effect of Moderate Aerobic Exercise Training on Endothelial Function and Arterial Stiffness in CKD Stages 3-4: A Randomized Controlled Trial.

Amaryllis H Van Craenenbroeck1, Emeline M Van Craenenbroeck2, Katrijn Van Ackeren3, Christiaan J Vrints2, Viviane M Conraads2, Gert A Verpooten4, Evangelia Kouidi5, Marie M Couttenye6.   

Abstract

BACKGROUND: Evidence of a beneficial effect of exercise training on mediators of vascular disease is accumulating in chronic kidney disease (CKD), but its effect on vascular function in vivo still has to be established. The present study was designed to investigate whether a formal aerobic exercise training program improves peripheral endothelial function in patients with CKD stages 3 to 4. STUDY
DESIGN: Randomized controlled trial with a parallel-group design. SETTING & PARTICIPANTS: 48 patients with CKD stages 3 to 4 without established cardiovascular disease were randomly assigned to either an exercise training program or usual care. 40 patients completed the study (exercise training, 19; usual care, 21). INTERVENTION: The 3-month home-based aerobic training program consisted of 4 daily cycling sessions of 10 minutes each at a target heart rate, calculated as 90% of the heart rate achieved at the anaerobic threshold. Patients in the usual-care group were given standard therapy. OUTCOMES: The primary outcome was peripheral endothelial function. Secondary outcomes were aerobic capacity, arterial stiffness, numbers of endothelial (EPCs) and osteogenic progenitor cells (OPCs), migratory function of circulatory angiogenic cells, and health-related quality of life. MEASUREMENTS: Endothelial function was assessed with flow-mediated dilation of the brachial artery, aerobic capacity by peak oxygen uptake (VO(2peak)), arterial stiffness by carotid-femoral pulse wave velocity, numbers of EPCs and OPCs by flow cytometry, circulatory angiogenic cell function by an in vitro migratory assay, and quality of life by the Kidney Disease Quality of Life-Short Form questionnaire.
RESULTS: Exercise training significantly improved VO(2peak) and quality of life, but not in vivo vascular function (flow-mediated dilation and carotid-femoral pulse wave velocity) or cellular markers for vascular function (EPC and OPC count and circulatory angiogenic cell migratory function). LIMITATIONS: Short duration and intermittent nature of the exercise intervention.
CONCLUSIONS: In patients with CKD stages 3 to 4 without overt cardiovascular disease, 3 months of aerobic exercise training improved VO(2peak) and quality of life, without altering endothelial function or arterial stiffness.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease (CKD); aerobic capacity; aerobic exercise; arterial stiffness; cardiovascular disease prevention; endothelial dysfunction; exercise training; intermittent training; quality of life; randomized controlled trial

Mesh:

Year:  2015        PMID: 25960303     DOI: 10.1053/j.ajkd.2015.03.015

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  37 in total

1.  Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.

Authors:  Amaryllis H Van Craenenbroeck; Kristien J Ledeganck; Katrijn Van Ackeren; Angelika Jürgens; Vicky Y Hoymans; Erik Fransen; Volker Adams; Benedicte Y De Winter; Gert A Verpooten; Christiaan J Vrints; Marie M Couttenye; Emeline M Van Craenenbroeck
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-16       Impact factor: 4.733

Review 2.  Clinical relevance of sarcopenia in chronic kidney disease.

Authors:  Ranjani N Moorthi; Keith G Avin
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-05       Impact factor: 2.894

Review 3.  Physical inactivity: a risk factor and target for intervention in renal care.

Authors:  Dorien M Zelle; Gerald Klaassen; Edwin van Adrichem; Stephan J L Bakker; Eva Corpeleijn; Gerjan Navis
Journal:  Nat Rev Nephrol       Date:  2017-01-31       Impact factor: 28.314

4.  Endothelial dysfunction correlates with exaggerated exercise pressor response during whole body maximal exercise in chronic kidney disease.

Authors:  Ryan M Downey; Peizhou Liao; Erin C Millson; Arshed A Quyyumi; Salman Sher; Jeanie Park
Journal:  Am J Physiol Renal Physiol       Date:  2017-03-08

5.  Effects of aerobic exercise on vascular function in nondialysis chronic kidney disease: a randomized controlled trial.

Authors:  Danielle L Kirkman; Meghan G Ramick; Bryce J Muth; Joseph M Stock; Ryan T Pohlig; Raymond R Townsend; David G Edwards
Journal:  Am J Physiol Renal Physiol       Date:  2019-02-27

6.  Effects of diet and exercise on adipocytokine levels in patients with moderate to severe chronic kidney disease.

Authors:  Nihal Aydemir; Mindy M Pike; Aseel Alsouqi; Samuel A E Headley; Katherine Tuttle; Elizabeth E Evans; Charles M Milch; Kelsey A Moody; Michael Germain; Loren Lipworth; Jonathan Himmelfarb; T A Ikizler; Cassianne Robinson-Cohen
Journal:  Nutr Metab Cardiovasc Dis       Date:  2020-04-21       Impact factor: 4.222

Review 7.  A Critical Review of Exercise Training in Hemodialysis Patients: Personalized Activity Prescriptions Are Needed.

Authors:  Kenneth R Wilund; João L Viana; Luis M Perez
Journal:  Exerc Sport Sci Rev       Date:  2020-01       Impact factor: 6.230

8.  Aerobic exercise in adults with chronic kidney disease (CKD): a meta-analysis.

Authors:  Gaiqin Pei; Yi Tang; Li Tan; Jiaxing Tan; Long Ge; Wei Qin
Journal:  Int Urol Nephrol       Date:  2019-07-22       Impact factor: 2.370

Review 9.  Cardiorespiratory Fitness and Atherosclerosis: Recent Data and Future Directions.

Authors:  Emile Mehanna; Anne Hamik; Richard A Josephson
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

Review 10.  The Vascular Endothelium in Chronic Kidney Disease: A Novel Target for Aerobic Exercise.

Authors:  Christopher R Martens; Danielle L Kirkman; David G Edwards
Journal:  Exerc Sport Sci Rev       Date:  2016-01       Impact factor: 6.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.